- Trials with a EudraCT protocol (4,463)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,463 result(s) found.
Displaying page 184 of 224.
| EudraCT Number: 2014-002666-76 | Sponsor Protocol Number: 200363 | Start Date*: 2015-06-17 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma | |||||||||||||
| Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005496-14 | Sponsor Protocol Number: MRZ60201_3072_1 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
| Full Title: Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity alone or comb... | |||||||||||||
| Medical condition: Upper limb spasticity or combined upper and lower limb spasticity in children and adolescents (age 2 - 17 years) with cerebral palsy | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002941-23 | Sponsor Protocol Number: GWEP1423 | Start Date*: 2015-09-30 | |||||||||||
| Sponsor Name:GW Research Ltd. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syn... | |||||||||||||
| Medical condition: Lennox-Gastaut syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003400-39 | Sponsor Protocol Number: NGLU-CL02 | Start Date*: 2014-07-15 | ||||||||||||||||
| Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
| Full Title: A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||||||||||||||||||
| Medical condition: Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo B | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) ES (Temporarily Halted) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-006013-34 | Sponsor Protocol Number: 115884 | Start Date*: 2013-01-11 | ||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
| Full Title: A phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine when administered to childr... | ||||||||||||||||||||||||||||
| Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children 2-17 years of age who are at increased risk of pneumococcal infection. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA PL (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2012-000658-67 | Sponsor Protocol Number: DEEP-1 | Start Date*: 2012-07-31 | |||||||||||
| Sponsor Name:Consorzio per Valutazioni Biologiche e Farmacologiche | |||||||||||||
| Full Title: Multi-centre, oral single dose experimental and modelling study to evaluate the pharmacokinetics of deferiprone in patients aged from 1 month to less than 6 years of age affected by transfusion-dep... | |||||||||||||
| Medical condition: chronic iron overload | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002582-35 | Sponsor Protocol Number: MCI-196-E16 | Start Date*: 2013-03-14 | |||||||||||
| Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC) | |||||||||||||
| Full Title: A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on ... | |||||||||||||
| Medical condition: Hyperphosphataemia | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000389-39 | Sponsor Protocol Number: VX12-770-112 | Start Date*: 2012-10-25 | |||||||||||
| Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
| Full Title: A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation | |||||||||||||
| Medical condition: cystic fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006749-18 | Sponsor Protocol Number: HE06-001-C P4 | Start Date*: 2009-06-26 | |||||||||||
| Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
| Full Title: Efficacy and safety of 6 % hydroxyethyl starch 130/0.4 (Voluven®) vs. 5% HSA in volume replacement therapy during elective open-heart surgery in paediatric patients | |||||||||||||
| Medical condition: Volume replacement therapy during elective open-heart surgery in paediatric patients | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002246-41 | Sponsor Protocol Number: BP29420 | Start Date*: 2014-10-23 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6885247 FOLLOWING 12 WEEKS OF T... | |||||||||||||
| Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002427-28 | Sponsor Protocol Number: CIT-003-01 | Start Date*: 2018-10-24 |
| Sponsor Name:Asklepion Pharmaceuticals, LLC | ||
| Full Title: A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acut... | ||
| Medical condition: Post-operative pulmonary dysfunction induced by cardiopulmonary bypass in pediatric subjects undergoing surgery for congenital heart defects. | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-004613-34 | Sponsor Protocol Number: NordLOTS protocol 1.4 | Start Date*: 2008-03-14 | ||||||||||||||||
| Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP) | ||||||||||||||||||
| Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar... | ||||||||||||||||||
| Medical condition: Obsessive Compulsive Disorder | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Ongoing) DK (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2008-005855-61 | Sponsor Protocol Number: 1100.1518 | Start Date*: 2009-05-20 |
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
| Full Title: An open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of nevirapine extended release tablets in HIV-1 infected children, with an optional extension ... | ||
| Medical condition: HIV-1 infected children under antiretroviral therapy | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2010-022872-30 | Sponsor Protocol Number: PALO-10-20 | Start Date*: 2011-08-04 | ||||||||||||||||
| Sponsor Name:Helsinn Healthcare SA | ||||||||||||||||||
| Full Title: A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatr... | ||||||||||||||||||
| Medical condition: Study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) HU (Completed) AT (Completed) BG (Completed) EE (Completed) DE (Completed) FR (Ongoing) CZ (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-003401-26 | Sponsor Protocol Number: 400-12-006 | Start Date*: 2014-05-16 |
| Sponsor Name:Ethicon Inc. | ||
| Full Title: A Prospective, Randomized, Controlled, Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Hemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non‐Cardiac) Surgery in Pediatric P... | ||
| Medical condition: Abdominal, Retroperitoneal, Pelvic or Thoracic (Non‐Cardiac) Surgery | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: GB (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-018730-51 | Sponsor Protocol Number: 113977 | Start Date*: 2010-11-24 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A phase IIIb, open, multi-centre, controlled study to assess the long-term persistence of antibodies after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus-t... | |||||||||||||
| Medical condition: Vaccination of children 2 to 10 years of age against invasive disease caused by meningococcal serogroups A, C, W-135, and Y. | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-015817-31 | Sponsor Protocol Number: OC3-DB-02 | Start Date*: 2009-12-01 | |||||||||||
| Sponsor Name:OxThera IP AB | |||||||||||||
| Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria | |||||||||||||
| Medical condition: primary hyperoxaluria | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-010108-27 | Sponsor Protocol Number: P05574 | Start Date*: 2012-10-26 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and B... | |||||||||||||
| Medical condition: Children 5 to 11 years of age with persistent asthma. | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006220-19 | Sponsor Protocol Number: SUM-2006/01-INT | Start Date*: 2008-11-27 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:PLIVA Hrvatska d.o.o. | ||||||||||||||||||||||||||||||||||||||
| Full Title: Safety and Efficacy of Sumamed® Therapy in the Treatment of Respiratory Tract Infections in Adults and Children: International, Multicenter, Non-Comparative Study | ||||||||||||||||||||||||||||||||||||||
| Medical condition: acute pharyngitis/tonsilitis acute sinusitis acute otitis media acute exacerbation of chronic bronchitis community acquired pneumonia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: SI (Completed) CZ (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-003359-19 | Sponsor Protocol Number: GALPED1001 | Start Date*: 2007-08-07 | |||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
| Full Title: An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome | |||||||||||||
| Medical condition: Children with Down syndrom | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.